Media coverage about Rite Aid (NYSE:RAD) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rite Aid earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.7517690371256 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Hot Mover of the Day – Rite Aid Corporation (NYSE: RAD) – Stocks Market Cap (stocksmarketcap.com)
- ‘Exhausted’ Toys ‘R’ Us suppliers weigh options as huge retailer shuts – Yahoo Finance (finance.yahoo.com)
- With An ROE Of 13.22%, Has Rite Aid Corporation’s (NYSE:RAD) Management Done Well? (finance.yahoo.com)
- CD 2007-CD4 Commercial Mortgage Trust — Moody’s Affirms Three Classes of CD 2007-CD4 (finance.yahoo.com)
- Health Dialog Chief Medical Officer Dr. Peter Goldbach to Speak at National Quality Forum Workshop on Shared Decision Making (finance.yahoo.com)
RAD has been the topic of several analyst reports. Vetr upgraded shares of Rite Aid from a “hold” rating to a “strong-buy” rating and set a $2.54 target price on the stock in a report on Tuesday, January 16th. Deutsche Bank initiated coverage on shares of Rite Aid in a report on Monday, December 4th. They issued a “hold” rating and a $2.25 target price on the stock. Zacks Investment Research lowered shares of Rite Aid from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Evercore ISI began coverage on shares of Rite Aid in a report on Thursday, January 4th. They set an “underperform” rating and a $1.50 price objective on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Rite Aid has an average rating of “Hold” and a consensus target price of $2.33.
TRADEMARK VIOLATION WARNING: “Rite Aid (NYSE:RAD) Receiving Somewhat Positive Media Coverage, Analysis Finds” was reported by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/2018/03/22/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-rite-aid-rad-stock-price/1971503.html.
About Rite Aid
Rite Aid Corporation is a retail drugstore chain. The Company’s segments include Retail Pharmacy and Pharmacy Services. The Company operates under The Rite Aid name. It operates approximately 4,560 stores in over 30 states across the country and in the District of Columbia. The Company’s Retail Pharmacy segment consists of Rite Aid stores, RediClinic and Health Dialog.
Receive News & Ratings for Rite Aid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rite Aid and related companies with MarketBeat.com's FREE daily email newsletter.